

To

The Honourable

Mr Adonis Georgiadis, Minister of Health

Cc.: Mr Stavros Evangelatos, Head of the Directorate of Medicinal Products and Pharmacies

Mr B. Karathanos, Advisor of the Minister of Health Mr Ath. Plevris, Advisor of the Minister of Health

Chalandri, February 21, 2014

Subject: High priority issues

Dear Minister,

After the rather fruitful meeting we held, we kindly request for your actions for the prompt implementation of the issues we discussed and agreed upon which concern:

- **A.** The **Correct Re-communication of the Prices Bulletin** within the following days with corrections regarding:
 - a) The codes that concern the on-patent products that have been priced with horizontal decreases, in violation of the relevant laws.
 - b) The codes that concern unique products, which have no generic with recorded sales.
 - c) The codes that are not included in the Prices Bulletin, while they show recorded sales or are destined for exports.
- **B.** Prompt Issue of a corrective Prices Bulletin, following the examination of all objections raised by the companies and relate to the problems occurring with the reference countries, the reductions, the medicinal products produced domestically and other issues.
- C. The Directorate of Prices of Medicinal Products of the Ministry must issue, upon the request of the companies, a certificate that an objection has been raised for the specific product, thus the prices included in the Prices Bulletin is temporary and consequently, must not be taken into account.
- D. A Revised Positive List must be promptly issued, so that the cost of the innovative products that were priced on August 6 and were included in the List on February 13, must be reimbursed for all approved suggestions, as provided for by the relevant legislation and in accordance with the commitment of the Ministry of Health. It is reminded that for this reason, the 5% rebate was enacted as the entrance fee in the list. In order to secure the unobstructed access of patients to their treatments, a commitment must be granted for the full reimbursement of the cost of these products, without any limitations, until the revision of the Positive List.

We kindly request for your prompt actions.

Yours sincerely,

Constantine M. Frouzis President of SFEE/

Paschalis Apostolidis Vice President

Nikos Kefalas Vice President